Search Results
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
Die Behandlung mit SKY-0515 führt zu einer dosisabhängigen Verringerung des mHTT-Proteins im Blut um 62 % bei einer Dosis von 9 mg und zu einer dosisabhängigen Verringerung der PMS1-mRNA um 26 %. PMS1 ist ein Schlüsselfaktor für die somatische CAG-Repeat-Expansion und die HD-Pathologie.
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
Pengobatan dengan SKY-0515 yang bergantung pada dosis menghasilkan penurunan protein mHTT dalam darah sebesar 62% pada dosis 9 mg, dan penurunan mRNA PMS1 sebesar 26% yang bergantung pada dosis. PMS1 adalah pendorong utama ekspansi pengulangan CAG somatik dan patologi HD. SKY-0515
More news about: Skyhawk Therapeutics
Jan 28, 2026, 11:54 ET Skyhawk Therapeutics annonce les résultats intermédiaires à neuf mois de son essai clinique de Phase 1 du SKY-0515 comme traitement de la maladie de Huntington
Le traitement avec SKY-0515 entraîne une réduction de 62 %, proportionnelle à la dose administrée, de la protéine mHTT dans le sang à la dose de 9 mg et une réduction de 26 %, elle aussi proportionnelle à la dose administrée, de l'ARNm PMS1. Le PMS1 est un facteur clé de l'expansion répétée d'un trinucléotide
More news about: Skyhawk Therapeutics
Jan 28, 2026, 09:00 ET RO DEBUTS FIRST-EVER SUPER BOWL COMMERCIAL STARRING SERENA WILLIAMS TO LAUNCH "HEALTHIER ON RO" CAMPAIGN
were at the end of her career as a professional athlete. Recent lab results show that she has lowered her cholesterol by 30% since 2021, from 185 mg/dL to 129 mg/dL (typically, a patient's total cholesterol levels improve by 4.8% while on GLP-1 medication). As her cholesterol improved, her lifetime
More news about: Ro
Jan 28, 2026, 08:37 ET New Peer-Reviewed Publication Validates Exceptional Safety and Efficacy of Synovetin OA® for Dog Arthritis
microparticle device: a review and validation in mammalian models. Front. Vet. Sci. 2-25;12:1-13 doi: 10.3389/fvets.2025.1621296.Arno MG; Barnhard JA, Webb KR, et al. Tin-117m radiosynoviorthesis safely and effectively manages canine osteoarthritis with minimal radiation exposure: a narrative
More news about: Exubrion Therapeutics
Jan 28, 2026, 06:30 ET Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
total consideration of up to $400 million.The Surf Bio hyperconcentration technology is being developed to enable high concentrations of up to 500 mg/mL across a wide range of therapeutics, including monoclonal antibodies and small molecules, for delivery in a single auto-injector shot for at-home
More news about: Halozyme Therapeutics, Inc.
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
Léčba přípravkem SKY-0515 vede v závislosti na dávce ke snížení obsahu proteinu mHTT v krvi o 62 % a k redukci mRNA PMS1 o 26 % při dávce 9 mg. PMS1 je klíčovým faktorem expanze somatických CAG repetic a patologie HD. Přípravek SKY-0515 rovněž prokázal vynikající expozici centrálního nervového
More news about: Skyhawk Therapeutics
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
Liečba liekom SKY-0515 vedie k dávkovo závislému zníženiu hladiny proteínu mHTT v krvi o 62 % pri dávke 9 mg a k dávkovo závislému zníženiu hladiny mRNA proteínu PMS1 o 26 %. Proteín PMS1 je kľúčovým faktorom expanzie opakovaní somatického CAG a patológie HD.
More news about: Skyhawk Therapeutics
Jan 27, 2026, 15:49 ET DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
Jan 27, 2026, 12:48 ET PRE® BRANDS UNVEILS PROTEIN-FORWARD PACKAGING REFRESH THAT REDEFINES PREMIUM BEEF AT RETAIL
contain 37% fewer calories than USDA Choice options at the meat counter. They also offer up to 31g of protein per serving, up to 170 mg of omega-3s per serving, and up to 377mg of CLAs per serving, in addition to providing iron, zinc, and vitamin B."At its core, this packaging elevates beef's role
More news about: Pre Brands
Jan 27, 2026, 10:22 ET Skyhawk Therapeutics Công Bố Kết Quả Nghiên Cứu Tạm Thời trên Bệnh Nhân sau 9 Tháng tiến hành Thử Nghiệm Lâm Sàng Giai Đoạn 1 thuốc SKY-0515 để Điều Trị bệnh Huntington
Việc điều trị bằng SKY-0515 làm giảm 62% lượng protein mHTT trong máu với liều 9mg (phụ thuộc liều) và giảm 26% lượng mRNA PMS1 (phụ thuộc liều). PMS1 là yếu tố then chốt thúc đẩy sự mở rộng lặp đoạn CAG trong tế bào soma và sự tiến
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:40 ET Skyhawk Therapeutics ogłasza dziewięciomiesięczne wyniki pośrednie badań klinicznych fazy 1 nad lekiem SKY-0515 stosowanym w leczeniu choroby Huntingtona
Leczenie za pomocą SKY-0515 powoduje zależne od dawki zmniejszenie stężenia białka mHTT we krwi o 62% przy dawce 9 mg oraz zależne od dawki zmniejszenie stężenia mRNA PMS1 o 26%. PMS1 jest kluczowym czynnikiem powodującym somatyczną ekspansję powtórzeń CAG i patologię
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:37 ET Skyhawk Therapeutics anuncia resultados de su ensayo clínico de SKY-0515 para la enfermedad de Huntington
El tratamiento con SKY-0515 produce reducciones dependientes de la dosis de la proteína mHTT en sangre del 62 % con la dosis de 9 mg, y una reducción dependiente de la dosis del ARNm de PMS1 del 26 %. PMS1 es un factor clave en la expansión de repeticiones CAG somáticas y la patología
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:00 ET Theo Brings Yield-Bearing Gold Onchain via Regulated Tokenized Fund Structure
Available soon across major DeFi venues, including Hyperliquid, Uniswap, Morpho, and Pendle, thGOLD is built on the MG999 On-Chain Gold Fund ("MG999"), a tokenised secured private credit fund managed by FundBridge Capital partnering with Mustafa Gold, and powered by Libeara, a tokenization
More news about: Theo Network
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
updatePaxalisib continues to demonstrate a generally favorable safety and tolerability profile when combined with pembrolizumab and chemotherapy at the 30 mg daily doseThe ongoing Phase 1b trial is a multi-center, open-label, randomized study initiated in June 2025 designed to evaluate the safety,
More news about: Kazia Therapeutics Limited
Jan 27, 2026, 08:00 ET 스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표
SKY-0515 투여 결과 9mg 용량에서 혈액 내 변이 헌팅틴 단백질(mHTT)이 62% 감소하는 등 용량 의존적 감소가 나타났으며, 체세포 CAG 반복 확장 및 헌팅턴병 병리학의 핵심 동인인 PMS1 mRNA는 26% 감소했다. 또한 SKY-0515는 우수한 중추신경계 노출을 입증했으며 전반적으로
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Treatment with SKY-0515 results in dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated
More news about: Skyhawk Therapeutics
Jan 26, 2026, 16:13 ET Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
with confirmed amyloid pathology.[2] Lecanemab is currently licensed as an IV infusion with a dosing regimen of once every two weeks (10 mg/kg). Eisai's submission states that following the initial dosing regimen of once every two weeks, after 18 months, patients will be transitioned to the
More news about: BioArctic
Jan 26, 2026, 11:29 ET Lucky Energy Reinvents On-the-Go Energy with the Launch of Its First Energy Gummies
variety pack will roll out next as the platform continues to expand.Each serving of Lucky Energy Gummies delivers:128 mg of caffeine7g of fiberA functional blend of maca, ginseng, beta-alanine, L-theanine, and taurineWith 7g of fiber per serving,
More news about: Lucky Beverage Company
Jan 26, 2026, 10:16 ET Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Week. The first real-world study showed patients prescribed tenapanor experienced a reduction in serum phosphate of nearly 1 mg/dL on average, with 45.3% experiencing at least 1 mg/dL reduction."We are excited to present new data on XPHOZAH at ASN's Kidney Week, including the first results from our
More news about: Equity Insider
Jan 25, 2026, 21:48 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
initiation and maintenance dosing for this progressive, relentless disease. Should the FDA approve the Leqembi Iqlik 500 mg subcutaneous (SC) dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly
More news about: BioArctic
Jan 25, 2026, 21:45 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
initiation and maintenance dosing for this progressive, relentless disease. Should the FDA approve the Leqembi Iqlik 500 mg subcutaneous (SC) dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly
More news about: BioArctic
Jan 25, 2026, 19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
Participants will be randomly assigned in a ratio of approximately 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 will be titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.About Ascletis Pharma Inc.Ascletis Pharma Inc. is
More news about: Ascletis Pharma Inc.
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Should the FDA approve the LEQEMBI IQLIK 500 mg SC dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly intravenous
More news about: Eisai Inc.